AUG 21, 2018 8:52 PM PDT

New Drug Delivery System for Precision Medicine

WRITTEN BY: Nouran Amin

A flexible drug delivery device providing controlled released offers the latest in personalized medicine. The device was developed by The Korea Advanced Institute of Science and Technology (KAIST) and offers a path to theragnosis.

An emerging medical technology, theragnosis, is receiving popularity as a key factor in advancing precision medicine by featuring simultaneous diagnosis and therapeutics. Theragnosis devices include smart contact lenses and microneedle patches that include physiological data sensors and drug delivery devices. The drug delivery systems are rooted for due to few side-effects, reliable therapeutic results, and minimal dosages in comparison to oral administration. In-human applications were recently conducted by some research groups for osteoporosis treatment research however, these applications have failed to demonstrate successful controlled release drug release through flexible drug delivery systems. Fortunately, for this microdevice, the research team guided under Professor Daesoo Kim from the Department of Biological Science and Professor Keon Jae Lee from the Department of Materials Science and Engineering created a device on a rigid substrate and transferred to an active drug delivery layer to the flexible substrate through an inorganic laser lift-off.

The developed device provided mechanical flexibility while maintaining the ability of precise administration for exact dosages at indicated times. The primary point of the device is to produce a gold cap layer that is directly placed on top of the microreservoir with the drugs inside; this had been seen as impossible in conventional microfabrication. Now, the drug delivery system can be applied to smart contact lenses or brain disease treatments by placing them into cramped and corrugated organs. Additionally, through wireless powering, the drug delivery device will represent a new platform for personalized medicine.

Experiments on animal models showed researchers that treating brain epilepsy was progressing well by releasing anti-epileptic medication through the drug delivery system. The team already proved through animal experimentation that treatment for brain epilepsy made progress by releasing anti-epileptic medication through the microdevice. This will further advance the applications of smart contact lenses, seeking effective therapeutic treatments for brain disease, and subcutaneous implantations during daily healthcare system use.

Source: Korea Advanced Institute of Science and Technology

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 27, 2019
Drug Discovery & Development
NOV 27, 2019
Vaccine Causes More Polio Cases than Wild Virus
The World Health Organization (WHO) has confirmed that 11 new cases of polio in five African countries including Nigeria, Congo and Angola were caused by a...
DEC 16, 2019
Drug Discovery & Development
DEC 16, 2019
IV Treatment for Traumatic Brain Injury
Scientists are now using exosomes intravenously as a method of cell-to-cell technology for treating patients with traumatic brain injury (TBI). They discov...
JAN 03, 2020
Drug Discovery & Development
JAN 03, 2020
Researchers Grow Psilocybin from E. Coli Bacteria
Previously considered to be narcotic, and under tight regulation as an illicit drug for decades, research from recent years on the possible medicinal prope...
JAN 13, 2020
Drug Discovery & Development
JAN 13, 2020
Vaccine Against Alzheimer's to Hit Clinical Trials
Currently Alzheimer’s disease is thought to affect around 50 million people around the world, with this figure doubling every year. Currently with no...
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Drug Targets Gastrointestinal Cancer
The FDA has recently approved Ayvakit (avapritinib) for the treatment of unresectable and metastatic gastrointestinal stromal tumor (GIST) that occurs most...
FEB 08, 2020
Cancer
FEB 08, 2020
Magic mushrooms help cancer patients' depression
A follow-up to a study originally published in the Journal of Psychopharmacology in 2016 reports the long-term benefits of a one-time, single-dose tre...
Loading Comments...